Can a slower dose of this cancer drug ease harsh side effects?
NCT ID NCT06001762
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether gradually increasing the dose of abemaciclib (a targeted cancer drug) can reduce side effects like diarrhea and help patients stick with treatment. It involves 90 people with early-stage, hormone receptor-positive, HER2-negative breast cancer who are also taking standard hormone therapy. The goal is to see if this slower approach is better tolerated than the usual fixed dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abemaciclib (a targeted cancer drug)
What this could lead to
If successful, this could lead to a better-tolerated way to take abemaciclib, reducing side effects like diarrhea and helping more patients complete their treatment.
What could go wrong
This is a small, early-phase trial (90 people) testing tolerability, not effectiveness. The dose-escalation strategy may still cause side effects or not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Dana-Farber Cancer Insitute at Londonderry Hospital
Londonderry, New Hampshire, 03053, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute at Foxborough
Foxborough, Massachusetts, 02035, United States
-
Dana-Farber Cancer Institute at Merrimack Valley
Methuen, Massachusetts, 01844, United States
-
Dana-Farber Cancer Institute at Milford
Milford, Massachusetts, 01757, United States
-
Dana-Farber Cancer Institute at South Shore
South Weymouth, Massachusetts, 02190, United States
-
Dana-Farber Cancer Institute at Steward St. Elizabeth's
Brighton, Massachusetts, 02135, United States
-
Eastern Maine Medical Center (Northern Light)
Brewer, Maine, 04412, United States
-
New England Cancer Specialists
Scarborough, Maine, 04074, United States
-
Stamford Hospital
Stamford, Connecticut, 06904, United States